Efficacy of ticagrelor and clopidogrel in treating unstable angina and their effects on serum inflammatory factors

To evaluate the comparative efficacy of Ticagrelor and Clopidogrel in treating patients with coronary heart disease and unstable angina, as well as their effects on serum inflammatory factors, thereby providing a solid foundation for future clinical diagnosis and treatment. The frequency of angina attacks in the Ticagrelor group was lower than in the Clopidogrel group (P< 0.05). The duration of angina and shortness of breath were also shorter in the Ticagrelor group (P<0.05). The levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinase-9 (MMP-9), lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), type 1 tissue plasminogen activator inhibitor (tPAI-1), homocysteine (Hcy), endothelin-1 (ET-1), tumor necrosis factor-alpha (TNF-?), platelet-derived growth factor (PDGF), brain natriuretic peptide (BNP), soluble CD40 ligand (sCD40L), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule (sLCAM-1), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglycerides (TG), as well as the incidence of MACCE events, were all lower in the Ticagrelor group compared to the Clopidogrel group (P<0.05), while high-density lipoprotein cholesterol (HDL-C) levels and overall efficacy were higher in the Ticagrelor group (P<0.05). Ticagrelor demonstrates superior therapeutic efficacy compared to Clopidogrel in patients with coronary heart disease and unstable angina, effectively reducing serum inflammatory factor levels.